It Seems TG Therapeutics Incorporated (NASDAQ:TGTX) Will Go Up. Just Reported Less Shorted Shares

February 20, 2018 - By Peter Erickson

 It Seems TG Therapeutics Incorporated (NASDAQ:TGTX) Will Go Up. Just Reported Less Shorted Shares

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 1.07, from 2.28 in 2017Q2. It fall, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported.
First Mercantile Tru Com has invested 0.04% in TG Therapeutics, Inc. (NASDAQ:TGTX). California State Teachers Retirement Systems has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Jennison Associates Limited Liability Corp invested in 0.02% or 1.24 million shares. Wells Fargo Communications Mn owns 54,141 shares or 0% of their US portfolio. Guggenheim Capital Ltd Liability Corp owns 101,935 shares for 0% of their portfolio. Credit Suisse Ag invested in 224,066 shares. Willingdon Wealth invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Voya Invest Management Limited Liability Corp owns 22,521 shares. Manufacturers Life Insur The reported 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Jpmorgan Chase holds 357,625 shares. Amer Gp has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). National Bank Of New York Mellon invested in 0% or 298,649 shares. Tudor Invest Corp Et Al holds 0.01% or 17,848 shares in its portfolio. Susquehanna Grp Llp reported 187,878 shares. 122,638 are held by Tiaa Cref Investment Management Lc.

Since December 29, 2017, it had 0 insider buys, and 1 sale for $272,051 activity.

The stock of TG Therapeutics Incorporated (NASDAQ:TGTX) registered a decrease of 11.25% in short interest. TGTX’s total short interest was 15.88 million shares in February as published by FINRA. Its down 11.25% from 17.89 million shares, reported previously. With 1.40 million shares average volume, it will take short sellers 11 days to cover their TGTX’s short positions. The short interest to TG Therapeutics Incorporated’s float is 47.31%.

The stock increased 4.51% or $0.55 during the last trading session, reaching $12.75. About 1.67 million shares traded or 11.48% up from the average. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since February 20, 2017 and is uptrending. It has outperformed by 43.84% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $900.82 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 12. The rating was maintained by FBR Capital with “Buy” on Wednesday, January 17. H.C. Wainwright maintained TG Therapeutics, Inc. (NASDAQ:TGTX) rating on Monday, December 11. H.C. Wainwright has “Buy” rating and $33.0 target. The rating was maintained by FBR Capital on Friday, February 2 with “Buy”. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. As per Thursday, October 6, the company rating was reinitiated by Brean Capital. As per Friday, May 27, the company rating was initiated by SunTrust. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Tuesday, March 7 by H.C. Wainwright. The rating was initiated by Suntrust Robinson on Friday, May 27 with “Buy”. The firm has “Buy” rating given on Friday, December 1 by B. Riley & Co.

More recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Globenewswire.com which released: “TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual …” on January 24, 2018. Also Seekingalpha.com published the news titled: “TG Therapeutics: Further Appreciation In 2018 Likely” on February 06, 2018. Seekingalpha.com‘s news article titled: “TG Therapeutics’ ublituximab continues to show treatment benefit in mid-stage …” with publication date: February 02, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: